<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dewesh Agrawal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Torrey, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1927603494">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will discuss medications commonly used for sedation and paralysis outside of the operating room during RSI in children. The approach to RSI outside of the operating room in children, including the steps involved in performing RSI and the selection of sedative and paralytic agents according to patient characteristics, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1546869965">
         <span class="h1">
          RAPID SEQUENCE INTUBATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         RSI describes a sequential process of preparation, sedation, and paralysis to facilitate safe, emergency tracheal intubation. Pharmacologic sedation and paralysis are induced in rapid succession to perform laryngoscopy and tracheal intubation with the goal of preventing aspiration. A simple, systematic approach to preparation and execution of the procedure is necessary in order to perform RSI successfully (
         <a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef111721" href="/z/d/graphic/111721.html" rel="external">
          figure 1
         </a>
         ). This approach is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2053951937">
         <span class="h1">
          SEDATION (INDUCTION) AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sedation (induction) agents are integral to the performance of RSI. They provide amnesia, unconsciousness, blunt sympathetic responses, and can improve intubating conditions.
        </p>
        <p>
         Each of the major induction agents in common use in children is discussed below and provided in the rapid overview (
         <a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">
          table 1
         </a>
         ). Further information about selection of sedatives and paralytics for RSI in children according to serious underlying conditions (eg, hemodynamic instability, increased intracranial pressure, status asthmaticus, or status epilepticus) is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of paralytic agent'
         </a>
         .)
        </p>
        <p>
         Additional discussion of pathophysiology and use of these agents for RSI outside of the operating room in adults is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H699746016">
         <span class="h2">
          Etomidate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         is an ultra-short-acting, imidazole derivative that produces reliable sedation and induction for RSI without causing significant hemodynamic compromise. It is an effective induction agent for most children undergoing RSI and is especially useful for patients with hypovolemic shock (eg, pediatric trauma patients), hypotensive patients with status epilepticus, and those with increased intracranial pressure (ICP). (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Etomidate'
         </a>
         .)
        </p>
        <p>
         The dose of
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         used in RSI is 0.3 mg/kg intravenous (IV) with a time to effect of approximately 15 to 45 seconds and a duration of effect at this dose of 10 to 12 minutes. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Etomidate'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         reliably decreases ICP and cerebral metabolic rate, suggesting that it has a neuroprotective effect. Etomidate also has a protective effect similar to thiopental for generalized seizure activity, although regional neuro-excitation has been described in adults. Myoclonus has been reported as an adverse effect associated with etomidate. It does not generally interfere with intubation in children when paralytics are also used [
         <a href="#rid1">
          1
         </a>
         ]. Such myoclonus has been misidentified as seizure activity, leading to incorrect recommendations that etomidate be avoided in patients with seizure disorders. If neuro-excitation is a concern, then benzodiazepine sedation (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ) may be provided after intubation. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'General use'
         </a>
         .)
        </p>
        <p>
         Because of its adrenocortical suppression, the 2010 Advanced Life Support recommendations provided by the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) suggest that
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         <strong>
          not
         </strong>
         be used routinely in children with septic shock. (See
         <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">
          "Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Airway and breathing'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         has undergone increasing use for RSI in children and observational studies and case series indicate that it produces good intubating conditions with minimal hemodynamic changes and a low frequency of adverse events, even in hypovolemic patients or those with limited cardiac reserve [
         <a href="#rid1">
          1-8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3917883154">
         <span class="h2">
          Ketamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is a dissociative anesthetic that is derived from phencyclidine. It produces rapid sedation (induction), amnesia, and analgesia while preserving protective airway reflexes. The dose of ketamine used in RSI is 1 to 2 mg/kg IV with a time to effect of 45 to 60 seconds and a duration of action of 10 to 20 minutes, depending upon dose. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is generally considered the preferred agent in children with septic shock because, unlike
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         , it does not cause adrenocortical suppression and, compared with other options (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , or thiopental) it does not cause hypotension. In addition, ketamine causes endogenous catecholamine release, thus augmenting heart rate and blood pressure in patients who are
         <strong>
          not
         </strong>
         catecholamine depleted. (See
         <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">
          "Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Airway and breathing'
         </a>
         .)
        </p>
        <p>
         However, the physician should make every effort to reverse hypovolemia and to provide direct-acting vasopressors to counteract hypotension prior to
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         administration because ketamine also has a direct negative inotropic effect. When given to patients in septic shock with exhausted endogenous catecholamine stores, it has rarely been associated with cardiac arrest that has been attributed to negative inotropic effect that is not overcome by release of endogenous catecholamines [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         .)
        </p>
        <p>
         Catecholamine release associated with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         also results in bronchodilation in animal studies. Although direct evidence is lacking in children, it is suggested as the preferred agent for RSI in patients with status asthmaticus [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'General use'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         may elevate ICP and theoretically has the potential for worsening ICP in patients with head injury, although evidence for adverse clinical effects in this population is weak. On the other hand, ketamine has anticonvulsant properties and may benefit patients with neurologic injury by increasing cerebral perfusion, particularly those who are hypotensive. Thus, it may still be appropriate for RSI in patients with increased ICP associated with low or normal blood pressure. However, we generally avoid it in patients who are hypertensive. The use of ketamine for patients with head injury is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Elevated intracranial pressure'
         </a>
         .)
        </p>
        <p>
         The
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         dose for RSI is well below doses associated with increased intraocular pressure. However, it frequently causes vomiting. Thus, in most patients with concern for an open globe, other sedatives are better choices. (See
         <a class="medical medical_review" href="/z/d/html/6513.html" rel="external">
          "Open globe injuries: Emergency evaluation and initial management", section on 'Initial emergency assessment and treatment'
         </a>
         .)
        </p>
        <p>
         Initial studies in children indicated
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         was a potent sialogogue and recommended premedication with
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         [
         <a href="#rid11">
          11,12
         </a>
         ]. However, more recent evidence suggests that excessive salivation is uncommon in doses typically used for RSI. As an example, in 947 pediatric sedations performed without atropine, significant salivation was reported in approximately 1 percent of patients and was felt to cause airway complications in only one instance [
         <a href="#rid13">
          13
         </a>
         ]. Thus, the use of anticholinergic premedication for ketamine sedation during RSI is
         <strong>
          not
         </strong>
         routinely necessary.
        </p>
        <p class="headingAnchor" id="H2200274623">
         <span class="h2">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         is a highly lipid soluble, nonbarbiturate sedative-hypnotic that binds the gamma-aminobutyric acid
         <sub>
          A
         </sub>
         (GABA
         <sub>
          A
         </sub>
         ) receptor complex with resulting sedation (induction) and amnesia.
        </p>
        <p>
         The initial dose of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         used in hemodynamically stable children undergoing RSI is 1 to 1.5 mg/kg with an onset of effect in 15 to 45 seconds and duration of action of 5 to 10 minutes, depending upon dose. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Propofol'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         is a good choice for RSI in hemodynamically stable patients with status epilepticus. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         .)
        </p>
        <p>
         However, the following characteristics limit its usefulness for RSI for patients who are hemodynamically unstable (see
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Propofol'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasodilatation and myocardial depression are even more pronounced with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         than with thiopental.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The neuroprotective effect of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         can be offset by a decrease in cerebral perfusion pressure as a result of decreased arterial pressure.
        </p>
        <p>
        </p>
        <p>
         Although the manufacturer lists egg or soybean allergies as contraindications to the use of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , significant allergic reactions to the newer preparation of the drug appear to be rare. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Hypnotic induction agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H826014118">
         <span class="h2">
          Midazolam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         is a rapid-acting benzodiazepine that binds the gamma-aminobutyric acid
         <sub>
          A
         </sub>
         (GABA
         <sub>
          A
         </sub>
         ) receptor complex with potent amnestic and anticonvulsant properties, as well as a short duration of action.
        </p>
        <p>
         The dose of
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         used for RSI is 0.2 to 0.3 mg/kg IV with a time to effect of 2 to 3 minutes and a duration of action of that is approximately 30 to 45 minutes, depending upon dose. This dose is significantly higher than what is typically used for procedural sedation.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         is appropriate for RSI in hemodynamically stable children with status epilepticus. However, several factors make other agents preferable for most patients (see
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Benzodiazepines'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In children, the time to clinical effect is longer for
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         than for any of the other sedative agents. Underdosing of midazolam may contribute to this observation [
         <a href="#rid14">
          14
         </a>
         ]. However, several reports have noted that it inconsistently induces unconsciousness, even at appropriate doses [
         <a href="#rid10">
          10,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         also causes respiratory depression. As a result, patients may develop apnea before they have received a paralytic agent, decreasing the effectiveness of preoxygenation prior to intubation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Finally,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         has a myocardial depressant effect and produces a dose-related reduction in systemic vascular resistance. It should
         <strong>
          not
         </strong>
         be used in hemodynamically compromised patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2758160221">
         <span class="h2">
          Fentanyl
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          Fentanyl
         </a>
         is a synthetic centrally acting opioid agonist that has a rapid onset of action, short duration of effect, and lack of histamine release.
        </p>
        <p>
         The suggested dose of
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         for sedation (induction) during RSI ranges from 1 to 5 mcg/kg [
         <a href="#rid16">
          16
         </a>
         ]. For children who are not in shock, the suggested dose is 3 mcg/kg (up to 5 mcg/kg). For children in shock, the physician should start at 1 mcg/kg and titrate to effect while monitoring hemodynamic status.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          Fentanyl
         </a>
         should be given slowly over 30 to 60 seconds to avoid respiratory depression that may compromise preoxygenation. Chest wall rigidity with inability to ventilate is a rare complication that is typically associated with rapid infusion and higher doses but has been reported with doses as low as 1 mcg/kg in neonates and infants [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Although evidence is lacking,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         is favored by some experts for RSI in children with cardiogenic shock or shock with suspected catecholamine depletion (eg, patients with persistent hypotension despite receiving vasopressors).
        </p>
        <p class="headingAnchor" id="H2660338946">
         <span class="h2">
          Thiopental
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thiopental is no longer readily available nor widely used as a sedation (induction) agent for RSI. For those with access to these medications, a brief overview of its use is provided here.
        </p>
        <p>
         The dose of thiopental used in RSI is 3 to 5 mg/kg IV with a time to effect of &lt;30 seconds and a duration of effect of 5 to 10 minutes, depending upon dose. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Barbiturates'
         </a>
         .)
        </p>
        <p>
         Thiopental is a short-acting barbiturate with a rapid onset of action that has been used extensively for sedation and induction in RSI. It may provide better intubating conditions than
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         , as was demonstrated in one large, prospective, observational series of adults and children where successful intubation on the first attempt was more likely with thiopental than with etomidate [
         <a href="#rid4">
          4
         </a>
         ]. However, thiopental causes vasodilatation and myocardial depression, resulting in a decrease in systolic blood pressure. Thus, it should
         <strong>
          not
         </strong>
         be used in patients with cardiovascular instability. Furthermore, thiopental causes histamine release that may contribute to a decrease in systolic blood pressure and may exacerbate bronchospasm in patients with asthma or bronchospasm from other causes. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Barbiturates'
         </a>
         .)
        </p>
        <p>
         As long as cerebral perfusion pressure is maintained, thiopental provides neuroprotection through reduction in cerebral oxygen consumption and blood flow. It also has anticonvulsant properties, making it a preferred sedative for patients with neurologic injury who are hemodynamically stable. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Barbiturates'
         </a>
         .)
        </p>
        <p>
         Production of thiopental was discontinued by the sole United States manufacturer in 2011, and it is not available in the United States, Canada, and many other countries [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2175222855">
         <span class="h1">
          PARALYTIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paralytic agents provide complete muscle relaxation, which facilitates rapid tracheal intubation. They do not provide sedation, analgesia, or amnesia. As a result, a sedative agent must also be used both for RSI and when paralysis is maintained after intubation. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         .)
        </p>
        <p>
         Each of the major paralytic agents in common use for pediatric RSI is provided in the rapid overview (
         <a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">
          table 1
         </a>
         ) and discussed below. Further information about each of these drugs including pathophysiology and use in adults is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2614546565">
         <span class="h2">
          Succinylcholine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          Succinylcholine
         </a>
         is the classic depolarizing agent, which acts as an analogue of acetylcholine (ACh) with stimulation of all cholinergic receptors throughout the parasympathetic and sympathetic nervous systems. Succinylcholine binds directly to the postsynaptic ACh receptors of the motor endplate, causing continuous stimulation of these receptors. This effect leads to transient fasciculations followed by muscular paralysis. Evidence regarding the relative efficacy of succinylcholine versus other paralytic agents is presented in the next section. (See
         <a class="local">
          'Rocuronium'
         </a>
         below.)
        </p>
        <p>
         The dose of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         for infants and children younger than two years of age is 2 mg/kg intravenous (IV), which is higher than that recommended for older children and adolescents. This is because succinylcholine is rapidly distributed in extracellular water, and infants and young children have a larger relative volume of extracellular fluid [
         <a href="#rid19">
          19,20
         </a>
         ]. For older children and adolescents, the dose of succinylcholine is 1 to 1.5 mg/kg. Succinylcholine has a rapid onset of effect (30 to 60 seconds, IV) and short duration of action (4 to 6 minutes, IV). (See
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Succinylcholine'
         </a>
         .)
        </p>
        <p>
         Bradycardia following the administration of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         occurs more commonly in infants and children younger than five years of age. The risks of bradycardia and, sometimes, asystole are also more significant when repeated doses of succinylcholine are administered [
         <a href="#rid21">
          21,22
         </a>
         ]. To avoid these complications, many experts suggest pretreating with
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         for children younger than five years of age and for all patients when a second dose is required. Repeated doses of succinylcholine should be avoided whenever possible. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Pretreatment'
         </a>
         .)
        </p>
        <p>
         Due to adverse effects, the use of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         is
         <strong>
          absolutely
         </strong>
         contraindicated under the following circumstances (see
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Contraindications and side effects'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic skeletal muscle disease (eg, Becker or Duchenne muscular dystrophy)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Denervating neuromuscular disease (eg, cerebral palsy with paralysis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &gt;48 hours after burns, multiple traumas, or an acute denervating event (eg, stroke or spinal cord injury)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive crush injury with rhabdomyolysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of malignant hyperthermia in patient or relatives
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant hyperkalemia (eg, suggested by characteristic changes on electrocardiogram)
        </p>
        <p>
        </p>
        <p>
         Relative contraindications to the use of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intracranial pressure – Although evidence supports elevated ICP related to fasciculations in adults [
         <a href="#rid23">
          23
         </a>
         ], many experts do not regard the potential for increased ICP as a contraindication to use of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         in children with traumatic brain injury. (See
         <a class="medical medical_review" href="/z/d/html/6566.html" rel="external">
          "Severe traumatic brain injury (TBI) in children: Initial evaluation and management", section on 'Rapid sequence intubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intraocular pressure [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known pseudocholinesterase deficiency (risk for prolonged duration of action) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Elevated intracranial pressure (ICP) with the use of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         has been reported in animal studies and in humans with brain tumors. Although a systematic review found no definitive evidence that succinylcholine causes a rise in ICP in humans with brain injury, the available studies are small and of poor quality [
         <a href="#rid24">
          24
         </a>
         ]. Thus, most experts do not regard the potential for increased ICP as a contraindication to use of succinylcholine for RSI.
        </p>
        <p class="headingAnchor" id="H143399509">
         <span class="h2">
          Rocuronium
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          Rocuronium
         </a>
         is a nondepolarizing paralytic agent that induces muscle paralysis by competitive antagonism at the nicotinic cholinergic receptor. At a dose of 1 mg/kg, it has a rapid onset of effect (30 to 60 seconds, IV), but a duration of action that is considerably longer than
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         (30 to 40 minutes) [
         <a href="#rid6">
          6
         </a>
         ]. For this reason, succinylcholine is favored over rocuronium for RSI when rapid reversal with
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          sugammadex
         </a>
         is not available, especially if a difficult airway is anticipated. (See
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Succinylcholine'
         </a>
         .)
        </p>
        <p>
         We suggest using
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         , at a dose of 1 mg/kg, as the paralytic agent for RSI when
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         may be contraindicated. Superior intubating conditions are a more important consideration than prolonged duration of action under these circumstances.
        </p>
        <p>
         When
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          sugammadex
         </a>
         is readily available,
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         , in a dose of 1 mg/kg, followed by sugammadex reversal may be equivalent to
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         with respect to intubating conditions and avoids the problem of prolonged paralysis, although evidence is limited. (See
         <a class="local">
          'Sugammadex'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          Rocuronium
         </a>
         has none of the adverse effects of
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          succinylcholine
         </a>
         , such as bradycardia, hyperkalemia, or malignant hyperthermia, making it a safe and efficacious alternative. As a result, some experts prefer the disadvantage of a longer duration of paralysis with rocuronium to the small risk of using succinylcholine for a child with an undiagnosed contraindication, such as a congenital myopathy or malignant hyperthermia [
         <a href="#rid10">
          10
         </a>
         ]. In addition, in a meta-analysis of 26 trials (3 in children), rocuronium at a dose of 1 mg/kg was equivalent to succinylcholine for producing clinically acceptable intubating conditions [
         <a href="#rid25">
          25,26
         </a>
         ]. However, the duration of action of rocuronium is longer at the higher dose and succinylcholine is more likely to provide excellent intubating conditions.
        </p>
        <p class="headingAnchor" id="H341434373">
         <span class="h2">
          Vecuronium and pancuronium
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12877" href="/z/d/drug information/12877.html" rel="external">
          Vecuronium
         </a>
         is the nondepolarizing agent from which
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         was developed. Like rocuronium, it has a favorable safety profile. However, to achieve as rapid an onset of action as rocuronium, higher doses of vecuronium (eg, 0.15 to 0.2 mg/kg) must be used, which also prolongs paralysis in an unpredictable fashion unless reversed by
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          sugammadex
         </a>
         .
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12877" href="/z/d/drug information/12877.html" rel="external">
          Vecuronium
         </a>
         should be avoided in patients for whom endotracheal intubation is predicted to be difficult. In two trials that compared vecuronium with
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         for RSI, intubating conditions were less optimal in patients who received vecuronium compared with those who received rocuronium [
         <a href="#rid27">
          27,28
         </a>
         ]. For these reasons, its usefulness for RSI is limited.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12676" href="/z/d/drug information/12676.html" rel="external">
          Pancuronium
         </a>
         is a longer acting nondepolarizing neuromuscular blocking agent that should not be used for RSI outside of the operating room because of its slower onset of action and prolonged duration. Pancuronium also causes histamine release and has a pronounced vagolytic effect that increases heart rate, blood pressure, and cardiac output.
        </p>
        <p class="headingAnchor" id="H282701214">
         <span class="h1">
          SUGAMMADEX
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          Sugammadex
         </a>
         is a novel agent that encapsulates and binds with molecules of
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         and other steroidal neuromuscular blocking agents (NMBAs; eg,
         <a class="drug drug_pediatric" data-topicid="12877" href="/z/d/drug information/12877.html" rel="external">
          vecuronium
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12676" href="/z/d/drug information/12676.html" rel="external">
          pancuronium
         </a>
         ), thereby rapidly reversing their neuromuscular blocking effects. Limited evidence suggests that sugammadex has a similar safety profile in children 2 to 17 years of age as in adults [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         .)
        </p>
        <p>
         Although variations in individual patient response have been noted, a dose of 16 mg/kg can reverse profound rocuronium-induced blockade within three minutes. Cardiac arrhythmias, including marked bradycardia, may occur after administration of
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          sugammadex
         </a>
         . Patients with cardiac disease appear to be at increased risk. Although rare, anaphylaxis within minutes after sugammadex administration has occurred, and the incidence is proportional to the administered dose. Thus, full electrocardiography (ECG) monitoring should be continued during and after administration of sugammadex, and resuscitation drugs, including
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         , should be immediately available.
        </p>
        <p class="headingAnchor" id="H3958196485">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128162.html" rel="external">
          "Society guideline links: Airway management in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3098814639">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Rapid sequence intubation (RSI) describes a sequential process of preparation, sedation, and paralysis to facilitate safe, emergency tracheal intubation. Pharmacologic sedation and paralysis are induced in rapid succession to perform laryngoscopy and tracheal intubation. (See
         <a class="local">
          'Rapid sequence intubation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid overview and checklist
         </strong>
         – A rapid overview with drug doses and a checklist provide a simple systematic approach to preparation and performance of RSI in children (
         <a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef111721" href="/z/d/graphic/111721.html" rel="external">
          figure 1
         </a>
         ). This approach is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sedation (induction)
         </strong>
         – Sedation (induction) agents are integral to the performance of RSI. They provide amnesia, unconsciousness, blunt sympathetic responses, and can improve intubating conditions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         – Etomidate is an effective induction agent for most children undergoing RSI and is especially useful for patients with hypovolemic shock (eg, pediatric trauma patients), hypotensive patients with status epilepticus, and those with increased intracranial pressure (ICP). (See
         <a class="local">
          'Etomidate'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of sedation (induction) agent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         – Ketamine is generally considered the preferred agent in children with septic shock because, unlike
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         , it does not cause adrenocortical suppression and, compared with other options (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , or thiopental), it does not cause hypotension. (See
         <a class="local">
          'Ketamine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         <strong>
          and
         </strong>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         – Propofol and midazolam are appropriate for RSI in hemodynamically stable children with status epilepticus. Otherwise, other agents are preferable because both agents can cause hypotension or myocardial depression. (See
         <a class="local">
          'Propofol'
         </a>
         above and
         <a class="local">
          'Midazolam'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          Fentanyl
         </a>
         – Fentanyl is favored by some experts for RSI in selected children with cardiogenic shock or shock with suspected catecholamine depletion (eg, patients with persistent hypotension despite receiving vasopressors). (See
         <a class="local">
          'Fentanyl'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paralytic agents
         </strong>
         – Paralytic agents provide complete muscle relaxation, which facilitates rapid tracheal intubation. They do not provide sedation (induction), analgesia, or amnesia. Thus, a sedation (induction) agent must also be used both for RSI and when paralysis is maintained after intubation.
         <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">
          Succinylcholine
         </a>
         , if not contraindicated, or
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          sugammadex
         </a>
         immediately available are suggested paralytic agents for children undergoing RSI. (See
         <a class="local">
          'Paralytic agents'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Selection of paralytic agent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="107775" href="/z/d/drug information/107775.html" rel="external">
          Sugammadex
         </a>
         – Sugammadex is a novel agent that encapsulates and binds with molecules of
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         and other steroidal neuromuscular blocking agents (NMBAs; eg,
         <a class="drug drug_pediatric" data-topicid="12877" href="/z/d/drug information/12877.html" rel="external">
          vecuronium
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12676" href="/z/d/drug information/12676.html" rel="external">
          pancuronium
         </a>
         ) thereby rapidly reversing their neuromuscular blocking effects. (See
         <a class="local">
          'Sugammadex'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Guldner G, Schultz J, Sexton P, et al. Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events. Acad Emerg Med 2003; 10:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagarin MJ, Chiang V, Sakles JC, et al. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care 2002; 18:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivilotti ML, Filbin MR, Murray HE, et al. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med 2003; 10:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokolove PE, Price DD, Okada P. The safety of etomidate for emergency rapid sequence intubation of pediatric patients. Pediatr Emerg Care 2000; 16:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ching KY, Baum CR. Newer agents for rapid sequence intubation: etomidate and rocuronium. Pediatr Emerg Care 2009; 25:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuckerbraun NS, Pitetti RD, Herr SM, et al. Use of etomidate as an induction agent for rapid sequence intubation in a pediatric emergency department. Acad Emerg Med 2006; 13:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oglesby AJ. Should etomidate be the induction agent of choice for rapid sequence intubation in the emergency department? Emerg Med J 2004; 21:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewhirst E, Frazier WJ, Leder M, et al. Cardiac arrest following ketamine administration for rapid sequence intubation. J Intensive Care Med 2013; 28:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelicof-Paul A, Smith-Lockridge A, Schnadower D, et al. Controversies in rapid sequence intubation in children. Curr Opin Pediatr 2005; 17:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page P, Morgan M, Loh L. Ketamine anaesthesia in paediatric procedures. Acta Anaesthesiol Scand 1972; 16:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyant GM. Intramuscular ketalar (CI-581) in paediatric anaesthesia. Can Anaesth Soc J 1971; 18:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown L, Christian-Kopp S, Sherwin TS, et al. Adjunctive atropine is unnecessary during ketamine sedation in children. Acad Emerg Med 2008; 15:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagarin MJ, Barton ED, Sakles JC, et al. Underdosing of midazolam in emergency endotracheal intubation. Acad Emerg Med 2003; 10:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salonen M, Kanto J, Iisalo E. Induction of general anesthesia in children with midazolam--is there an induction dose? Int J Clin Pharmacol Ther Toxicol 1987; 25:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewhirst E, Naguib A, Tobias JD. Chest wall rigidity in two infants after low-dose fentanyl administration. Pediatr Emerg Care 2012; 28:465.
          </a>
         </li>
         <li class="breakAll">
          phx.corporate-ir.net/phoenix.zhtml?c=175550&amp;p=irol-newsArticle&amp;ID=1518610&amp;highlight= (Accessed on August 01, 2011).
         </li>
         <li class="breakAll">
          Luten RC, Kissoon N. Approach to the pediatric airway. In: Manual of Emergency Airway Management, Walls RM, Murphy MF, Luten RC, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.212.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAllister JD, Gnauck KA. Rapid sequence intubation of the pediatric patient. Fundamentals of practice. Pediatr Clin North Am 1999; 46:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerardi MJ, Sacchetti AD, Cantor RM, et al. Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians. Ann Emerg Med 1996; 28:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson AL, Jerwood DC, Stokes MA. Routine suxamethonium in children. A regional survey of current usage. Anaesthesia 1996; 51:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfilippo F, Santonocito C, Veenith T, et al. The role of neuromuscular blockade in patients with traumatic brain injury: a systematic review. Neurocrit Care 2015; 22:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy M, Halford S, Walls R, Murphy M. In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review. Emerg Med J 2001; 18:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry J, Lee J, Wells G. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2003; :CD002788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCourt KC, Salmela L, Mirakhur RK, et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. Anaesthesia 1998; 53:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CE, Botero C, Holbrook C, et al. Rocuronium versus vecuronium during fentanyl induction in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth 1999; 13:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CE, Kovach B, Polk JD, et al. Prehospital tracheal intubating conditions during rapid sequence intubation: rocuronium versus vecuronium. Air Med J 2002; 21:26.
          </a>
         </li>
         <li class="breakAll">
          Bridion (sugammadex). Highlights of prescribing information. 6/2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s008lbl.pdf (Accessed on July 02, 2021).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113029 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12574010" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16187466" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12488834" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Rapid sequence intubation for pediatric emergency airway management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12782521" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Does the sedative agent facilitate emergency rapid sequence intubation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10698137" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The safety of etomidate for emergency rapid sequence intubation of pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19287283" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Newer agents for rapid sequence intubation: etomidate and rocuronium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636355" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Use of etomidate as an induction agent for rapid sequence intubation in a pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496686" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Should etomidate be the induction agent of choice for rapid sequence intubation in the emergency department?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22644454" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cardiac arrest following ketamine administration for rapid sequence intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15891426" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Controversies in rapid sequence intubation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4644713" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ketamine anaesthesia in paediatric procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5545737" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Intramuscular ketalar (CI-581) in paediatric anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18370983" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Adjunctive atropine is unnecessary during ketamine sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12670846" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Underdosing of midazolam in emergency endotracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3429063" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Induction of general anesthesia in children with midazolam--is there an induction dose?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245435" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Preparing for pediatric emergencies: drugs to consider.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561320" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Chest wall rigidity in two infants after low-dose fentanyl administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561320" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chest wall rigidity in two infants after low-dose fentanyl administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561320" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chest wall rigidity in two infants after low-dose fentanyl administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10629684" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rapid sequence intubation of the pediatric patient. Fundamentals of practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8669740" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8882256" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Routine suxamethonium in children. A regional survey of current usage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182388" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The role of neuromuscular blockade in patients with traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11559609" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535439" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rocuronium versus succinylcholine for rapid sequence induction intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9849280" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10527226" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Rocuronium versus vecuronium during fentanyl induction in patients undergoing coronary artery surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805764" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prehospital tracheal intubating conditions during rapid sequence intubation: rocuronium versus vecuronium.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
